ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics
PRQR Price/Volume Stats
| Current price | $1.99 | 52-week high | $3.29 |
| Prev. close | $1.86 | 52-week low | $1.11 |
| Day low | $1.87 | Volume | 134,000 |
| Day high | $2.07 | Avg. volume | 284,022 |
| 50-day MA | $2.14 | Dividend yield | N/A |
| 200-day MA | $1.77 | Market Cap | 161.90M |
PRQR Stock Price Chart Interactive Chart >
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Company Bio
ProQR Therapeutics is a biopharmaceutical company, focused on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. The company was founded in 2012 and is based in Leiden, the Netherlands.
Latest PRQR News From Around the Web
Below are the latest news stories about PROQR THERAPEUTICS NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
Is ProQR (PRQR) Stock a Solid Choice Right Now?ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsDivestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU Transaction supports ProQR’s strategic focus on its proprietary Axiomer® RNA editing technology platform and continued advancement of pipeline LEIDEN, Netherlands & CAMB |
ProQR Announces Third Quarter 2023 Operating and Financial ResultsContinued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United States and successful defense against opposition to its IP in Japan€120.6 M cash and cash equivalents as of September 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE |
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA EditingLEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the United States and that it has successfully defended against an opposition to its IP in Japan. “The new patent that the USPTO granted to ProQR further expands the protectio |
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines ConferenceLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 a |
PRQR Price Returns
| 1-mo | -17.08% |
| 3-mo | -4.33% |
| 6-mo | 61.79% |
| 1-year | -13.48% |
| 3-year | -66.83% |
| 5-year | -82.45% |
| YTD | 0.51% |
| 2023 | -46.49% |
| 2022 | -53.81% |
| 2021 | 90.71% |
| 2020 | -57.62% |
| 2019 | -37.20% |
Continue Researching PRQR
Here are a few links from around the web to help you further your research on ProQR Therapeutics NV's stock as an investment opportunity:ProQR Therapeutics NV (PRQR) Stock Price | Nasdaq
ProQR Therapeutics NV (PRQR) Stock Quote, History and News - Yahoo Finance
ProQR Therapeutics NV (PRQR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...